3-((+/-)-2-CARBOXYPIPERAZIN-4-YL)PROPYL-1-PHOSPHONIC ACID (CPP) AND PHENCYCLIDINE PRODUCE A DEFICIT OF PASSIVE-AVOIDANCE RETENTION IN RATS

被引:35
作者
DENOBLE, VJ
JONES, KW
SCHAEFFER, CL
BAUERLE, LM
机构
[1] E.I. du Pont de Nemours, Co., Inc., Medical Products Department, Wilmington, DE 19880-0400
关键词
Benzodiazepines; CCP (3-((±)-2-carboxupiperazin-4-yl)-propyl-1-phosphonic acid); Passive avoidance deficit; Phencyclidine; Ro; 15-1788;
D O I
10.1016/0014-2999(90)90230-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
3-((±)-2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CCP), phencyclidine (PCP) and diazepam were evaluated for their ability to produce a deficit for a single trial step-through passive avoidance response in rats. Pretraining administration with CCP at doses ranging from 2.0 to 10.0 mg/kg s.c. significantly decreased retention latencies 24 h after passive avoidance training. Similar effects were found with PCP at doses ranging from 0.5 to 1.7 mg/kg s.c. and diazepam at doses between 5.0-18.0 mg/kg s.c. Pretraining administration with the benzodiazepine antagonist, RO15-1788 at doses between 0.1-15 mg/kg s.c., did not alter retention latencies. Co-administration of RO15-1788 (0.01-15.0 mg/kg s.c.) with CCP (6.0 mg/kg s.c.) or PCP (1.0 mg/kg s.c.) failed to block decreases in latencies. However, when RO15-1788 was co-administered with diazepam (9.0 mg/kg s.c.) a dose-related antagonism of diazepam's effects were found. These results suggest that the behavioral actions of CCP and PCP on passive avoidance retention are not mediated via the benzodiazepine receptor complex. © 1990.
引用
收藏
页码:197 / 202
页数:6
相关论文
共 29 条
  • [1] THE DISSOCIATIVE ANESTHETICS, KETAMINE AND PHENCYCLIDINE, SELECTIVELY REDUCE EXCITATION OF CENTRAL MAMMALIAN NEURONS BY N-METHYL-ASPARTATE
    ANIS, NA
    BERRY, SC
    BURTON, NR
    LODGE, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1983, 79 (02) : 565 - 575
  • [2] BENNETT DA, 1987, EXCITATORY AMINO ACI, P213
  • [3] EPISODIC LONG-TERM-MEMORY IN THE RAT - EFFECTS OF HIPPOCAMPAL-STIMULATION
    BIERLEY, RA
    KESNER, RP
    NOVAK, JM
    [J]. BEHAVIORAL NEUROSCIENCE, 1983, 97 (01) : 42 - 48
  • [4] BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274
  • [5] BENZODIAZEPINE ANTAGONIST RO 15-1788 - NEUROLOGICAL AND BEHAVIORAL-EFFECTS
    BONETTI, EP
    PIERI, L
    CUMIN, R
    SCHAFFNER, R
    PIERI, M
    GAMZU, ER
    MULLER, RKM
    HAEFELY, W
    [J]. PSYCHOPHARMACOLOGY, 1982, 78 (01) : 8 - 18
  • [6] DANYSZ E, 1988, FASEB J, V2, pA311
  • [7] CPP, A NEW POTENT AND SELECTIVE NMDA ANTAGONIST - DEPRESSION OF CENTRAL NEURON RESPONSES, AFFINITY FOR [H-3] D-AP5 BINDING-SITES ON BRAIN MEMBRANES AND ANTICONVULSANT ACTIVITY
    DAVIES, J
    EVANS, RH
    HERRLING, PL
    JONES, AW
    OLVERMAN, HJ
    POOK, P
    WATKINS, JC
    [J]. BRAIN RESEARCH, 1986, 382 (01) : 169 - 173
  • [8] DAVIS J L, 1987, Society for Neuroscience Abstracts, V13, P658
  • [9] DENOBLE VJ, 1988, EUROPEAN BEHAV PHARM, V2, P13
  • [10] DENSITY AND DISTRIBUTION OF NMDA RECEPTORS IN THE HUMAN HIPPOCAMPUS IN ALZHEIMERS-DISEASE
    GEDDES, JW
    CHANGCHUI, H
    COOPER, SM
    LOTT, IT
    COTMAN, CW
    [J]. BRAIN RESEARCH, 1986, 399 (01) : 156 - 161